Skip to main content
Top
Published in: Current Pain and Headache Reports 11/2023

07-09-2023 | Stroke | Uncommon and/or Unusual Headaches and Syndromes (F Cohen, Section Editor)

Post-stroke Headache

Authors: Monica Chan, Alison Thaler

Published in: Current Pain and Headache Reports | Issue 11/2023

Login to get access

Abstract

Purpose of Review

Stroke is a major health concern and a leading cause of long-term disability. Persistent post-stroke headache (PPSH) is a common complication of stroke yet little is known about its specific characteristics or optimal management. The purpose of this review is to discuss the epidemiology, presentation, and hypothesized pathophysiology of PPSH. Acute and preventive treatment options, as well as specific concerns regarding triptans and the newer CGRP antagonists, will be discussed in detail as well.

Recent Findings

The 2018 International Classification of Headache Disorders, 3rd edition (ICHD-3) was the first headache diagnostic manual to include criteria for PPSH and defines this disorder as an acute headache that develops in close temporal relation to stroke and persists beyond 3 months. Recent literature estimates the prevalence of PPSH to be somewhere between 1 and 23% of patients post-stroke. Presentation is variable, but most often mimics tension-type headache. There are no evidence-based guidelines on the optimal treatment of PPSH.

Summary

PPSH is a common but poorly understood complication of stroke. Given the significant disability burden that PPSH carries, the epidemiology and pathophysiology of PPSH, as well as the efficacy and safety of potential treatment options, warrant further investigation.
Literature
2.
3.
go back to reference •• Harriott AM, Karakaya F, Ayata C. Headache after ischemic stroke. Neurology. 2020;94:e75–e86. A systematic review of 50 studies examining the prevalence and characteristics of new-onset post-stroke headache. •• Harriott AM, Karakaya F, Ayata C. Headache after ischemic stroke. Neurology. 2020;94:e75–e86. A systematic review of 50 studies examining the prevalence and characteristics of new-onset post-stroke headache.
4.
go back to reference Olesen J. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211. Olesen J. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
5.
go back to reference Lai J, Harrison RA, Plecash A, Field TS, Lai J, Plecash A, et al. A narrative review of persistent post-stroke headache–a new entry in the international classification of headache disorders, 3rd Edition. Headache. 2018;58:1442–53. Lai J, Harrison RA, Plecash A, Field TS, Lai J, Plecash A, et al. A narrative review of persistent post-stroke headache–a new entry in the international classification of headache disorders, 3rd Edition. Headache. 2018;58:1442–53.
6.
go back to reference Hansen AP, Marcussen NS, Klit H, Andersen G, Finnerup NB, Jensen TS. Pain following stroke: a prospective study. Eur J Pain. 2012;16:1128–36.CrossRefPubMed Hansen AP, Marcussen NS, Klit H, Andersen G, Finnerup NB, Jensen TS. Pain following stroke: a prospective study. Eur J Pain. 2012;16:1128–36.CrossRefPubMed
7.
go back to reference Hansen AP, Marcussen NS, Klit H, Kasch H, Jensen TS, Finnerup NB. Development of persistent headache following stroke: a 3-year follow-up. Cephalalgia. 2015;35:399–409.CrossRefPubMed Hansen AP, Marcussen NS, Klit H, Kasch H, Jensen TS, Finnerup NB. Development of persistent headache following stroke: a 3-year follow-up. Cephalalgia. 2015;35:399–409.CrossRefPubMed
8.
go back to reference Carvalho Dias M, Martins T, Basílio G, Lucas Neto L, Caeiro L, Ferro JM, et al. Headache at the chronic stage of ischemic stroke. Headache. 2020;60:607–14. Carvalho Dias M, Martins T, Basílio G, Lucas Neto L, Caeiro L, Ferro JM, et al. Headache at the chronic stage of ischemic stroke. Headache. 2020;60:607–14.
9.
go back to reference •• Lebedeva ER, Ushenin AV, Gurary NM, Gilev DV, Kislyak NV, Olesen J. Persistent headache after first-ever ischemic stroke: clinical characteristics and factors associated with its development. J Headache Pain. 2020;23:1–10. A prospective cohort study examining the prevalence, characteristics, and treatment of PPSH. •• Lebedeva ER, Ushenin AV, Gurary NM, Gilev DV, Kislyak NV, Olesen J. Persistent headache after first-ever ischemic stroke: clinical characteristics and factors associated with its development. J Headache Pain. 2020;23:1–10. A prospective cohort study examining the prevalence, characteristics, and treatment of PPSH.
10.
go back to reference Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia. 2008;28:598–604.CrossRefPubMed Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia. 2008;28:598–604.CrossRefPubMed
11.
go back to reference Schmidt-Wilcke T, Leinisch E, Straube A, Kämpfe N, Draganski B, Diener HC, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483–6.CrossRefPubMed Schmidt-Wilcke T, Leinisch E, Straube A, Kämpfe N, Draganski B, Diener HC, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483–6.CrossRefPubMed
12.
go back to reference Seifert CL, Schönbach EM, Magon S, Gross E, Zimmer C, Förschler A, et al. Headache in acute ischaemic stroke: a lesion mapping study. Brain. 2016;139:217–26.CrossRefPubMed Seifert CL, Schönbach EM, Magon S, Gross E, Zimmer C, Förschler A, et al. Headache in acute ischaemic stroke: a lesion mapping study. Brain. 2016;139:217–26.CrossRefPubMed
13.
go back to reference Oliveira FAA, Sampaio Rocha-Filho PA. Headaches attributed to ischemic stroke and transient ischemic attack. Headache. 2019;59:469–76. Oliveira FAA, Sampaio Rocha-Filho PA. Headaches attributed to ischemic stroke and transient ischemic attack. Headache. 2019;59:469–76.
15.
go back to reference Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack Adams A, et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) Study. Headache. 2019;59:32.CrossRefPubMed Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack Adams A, et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) Study. Headache. 2019;59:32.CrossRefPubMed
16.
go back to reference Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–39. Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–39.
17.
go back to reference Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60:649–53. Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60:649–53.
18.
go back to reference Leroux E, Rothrock J. Triptans for migraine patients with vascular risks: new insights, new options. Headache. 2019;59:1589–96. Leroux E, Rothrock J. Triptans for migraine patients with vascular risks: new insights, new options. Headache. 2019;59:1589–96.
19.
go back to reference Zebenholzer K, Gall W, Gleiss A, Pavelic AR, Wöber C. Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database–a cohort study. Headache. 2022;62:604–12. Zebenholzer K, Gall W, Gleiss A, Pavelic AR, Wöber C. Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database–a cohort study. Headache. 2022;62:604–12.
20.
go back to reference Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, et al. Triptans and CGRP blockade–impact on the cranial vasculature. J Headache Pain. 2017;18:1–7.CrossRef Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, et al. Triptans and CGRP blockade–impact on the cranial vasculature. J Headache Pain. 2017;18:1–7.CrossRef
21.
go back to reference Robblee J, Harvey LK. Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep. 2022;26:647–55.CrossRefPubMed Robblee J, Harvey LK. Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep. 2022;26:647–55.CrossRefPubMed
22.
go back to reference Mulder IA, Li M, de Vries T, et al. Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88:771.CrossRefPubMedPubMedCentral Mulder IA, Li M, de Vries T, et al. Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88:771.CrossRefPubMedPubMedCentral
23.
go back to reference Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:E2211–21.CrossRefPubMedPubMedCentral Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:E2211–21.CrossRefPubMedPubMedCentral
24.
go back to reference Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.CrossRefPubMed Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.CrossRefPubMed
25.
go back to reference Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine. Neurology. 2020;95:e2487–99.CrossRefPubMedPubMedCentral Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine. Neurology. 2020;95:e2487–99.CrossRefPubMedPubMedCentral
26.
go back to reference Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030–40.CrossRefPubMed Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030–40.CrossRefPubMed
27.
go back to reference Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280–7.CrossRefPubMed Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280–7.CrossRefPubMed
28.
go back to reference Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37.CrossRefPubMed Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37.CrossRefPubMed
29.
go back to reference Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94:e1365–77.CrossRefPubMedPubMedCentral Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94:e1365–77.CrossRefPubMedPubMedCentral
30.
go back to reference Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241–54.CrossRefPubMedPubMedCentral Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241–54.CrossRefPubMedPubMedCentral
31.
go back to reference Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814–25.CrossRefPubMed Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814–25.CrossRefPubMed
32.
go back to reference Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887–98.CrossRefPubMedPubMedCentral Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887–98.CrossRefPubMedPubMedCentral
33.
go back to reference Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230–41.CrossRefPubMed Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230–41.CrossRefPubMed
34.
go back to reference Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51–60.CrossRefPubMed Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51–60.CrossRefPubMed
35.
go back to reference Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706.CrossRefPubMed Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706.CrossRefPubMed
36.
go back to reference Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:1–33. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:1–33.
Metadata
Title
Post-stroke Headache
Authors
Monica Chan
Alison Thaler
Publication date
07-09-2023
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 11/2023
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-023-01169-4

Other articles of this Issue 11/2023

Current Pain and Headache Reports 11/2023 Go to the issue

Anesthetic Techniques in Pain Management (D Wang, Section Editor)

Neurostimulation therapies for chronic pain

Regenerative Pain Medicine/Interventional Pain Medicine (E Cornett Bradley, Section Editor)

Analgesic Techniques for Rib Fractures—A Comprehensive Review Article

Anesthetic Techniques in Pain Management (D Wang, Section Editor)

SPECT/CT Scan: A New Diagnostic Tool in Pain Medicine

Secondary Headache (M Robbins, Section Editor)

Spontaneous Intracranial Hypotension in Pregnancy

Regenerative Pain Medicine/Interventional Pain Medicine (E Cornett Bradley, Section Editor)

Electronic Health Record Recording of Patient Pain: Challenges and Discrepancies